A Study of IBI363 in Combination With Bevacizumab or Furuitinib in Subjects With Advanced Colorectal Cancer

A Phase 1 study of IBI363 in combination with Bevacizumab or Furuitinib in Subjects with Advanced Colorectal Cancer

Trial Details

NCT ID
NCT06717880
Phase
PHASE1
Sponsor
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • IBI363 combined with Bevacizumab
  • IBI363 + Furuitinib
Locations (sample)
  • Wuhan, Hubei, China|30.58333,114.26667

Key Eligibility Criteria

  • Sign written informed consent and be able to comply with the program's visit schedule and related procedures.
  • Male or female subjects, age 18\~75 years.
  • Histologically or cytologically confirmed advanced colorectal cancer.
  • Subjects who have progressed on standard therapy, who are unsuitable for standard therapy, who do not have standard therapy, or who have refused st…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →